Endometrium Cancer
35
8
9
18
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 35 trials
94.7%
+8.2% vs benchmark
6%
2 trials in Phase 3/4
28%
5 of 18 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 18 completed trials
Clinical Trials (35)
The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
Predictive Clinical and Biological Parameters in Gynecological Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment
Development of a Molecular Diagnostic Tool for Endometrial Cancer.
Tumor-Infiltrating Lymphocytes in Endometrial Cancer
Effect of Physical Activity Intervention on Overweight and Obese Patients With Endometrial Cancer
A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer.
Effect of Motivational Interviewing on Posttraumatic Stress Symptoms and Posttraumatic Growth in Women with Endometrial Cancer
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
Suspension of the Pelvic and Abdominal Organs During Minimally Invasive Surgery
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
The Effect of Logotherapy on Mental Health in Gynecological Cancer Patients
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.